Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
Patient Enrollment on Track in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Currently Expected Second Half...
Palatin Technologies, Inc. ("Palatin" or the "Company") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based...
Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2022 operating results on Tuesday, May 17, 2022, before...
Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...
Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter, fiscal year 2022 operating results on Tuesday, February 15, 2022,...
Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that...
Palatin Technologies, Inc., (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate...
Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2022 operating results on Monday, November 15, 2021,...
Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2021 operating results on Wednesday, September...
Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN) announced that its 2021 Annual Meeting of Stockholders that convened on June 8, 2021 and...
Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN) a biopharmaceutical company developing first-in-class medicines based on molecules that...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.